TTRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025
Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
2.0M
+21.9%
1.6M
+30.6%
1.2M
-43.2%
2.2M
R&D
605.2K
+27.4%
475.1K
+334.1%
109.4K
+213.3%
34.9K
SG&A
1.4M
+19.6%
1.2M
+1.4%
1.1M
-47.3%
2.2M
Operating Income
-1984442
-21.9%
-1628060
-30.6%
-1246143
+43.2%
-2193570
EBITDA
-1940779
-18.2%
-1642511
-33.4%
-1231692
+43.5%
-2179415
Net Income
-6230868
-6.5%
-5849734
-502.5%
-970972
-447.9%
279.1K
EPS (Basic)
$-0.21
-5.0%
$-0.20
-566.7%
$-0.03
-400.0%
$0.01
EPS (Diluted)
$-0.21
-5.0%
$-0.20
-566.7%
$-0.03
-400.0%
$0.01
Shares (Diluted)
30.1M
+1.2%
29.8M
+1.1%
29.5M
+3.6%
28.4M
Turn Therapeutics (TTRX) — Financials